Skip to main content

Table 3 Conditions shown to respond to omalizumab/anti-IgE* therapy

From: Severe asthma and the omalizumab option

Condition Reference
Allergic rhinitis [66,69,85-89]
Allergic asthma:  
   • Moderate-severe persistent disease [55,64,90-94]
   • Steroid-sparing effect [57,95,96]
Churg-Strauss syndrome [97,98]
Peanut anaphylaxis* [52,70,71,99,100]
Uticaria [78]
Angioedema [101]
Immunotherapy reactions [102]
Rubber latex allergy [79]